Changing concepts of medical treatment of endometriosis

References

• Ranney B. Etiology prevention and inhibition of endometriosis. Clin Obstet Gynecol 1981; 23: 875–83
   Google Scholar
• Cramer DW, Wilson E, Stillman RJ, Berger MJ, Belislie S, Schiff I, Albrecht B, Gibson M, Stadel BV, Schoenbaum SC. The relation of endometriosis to menstrual characteristics smoking and exercise. JAMA 1986; 255: 1904–8
   PubMed Web of Science ®Google Scholar
• Drake TS, Grunert GM. The unsuspected pelvic factor in the infertility investigations. Fertil Steril 1980; 34: 27–32
   PubMedGoogle Scholar
• Strathy JH, Molgaard CA, Coulam CB, Melton LJ. Endometriosis and infertility: a laparoscopical study of endometriosis among fertile and infertile women. Fertil Steril 1982; 38: 667–72
   PubMed Web of Science ®Google Scholar
• Peterson EP, Behrman SJ. Laparoscopy of the infertile patient. Obstet Gynecol 1970; 36: 363–7
   PubMedGoogle Scholar
• Goldeneberg RL, Magendantz HG. Laparoscopy and the infertility evaluation. Obstet Gynecol 1976; 47: 410–4
   Google Scholar
• Hasson HM. Incidence of endometriosis in diagnostic laparoscopy. J Reprod Med 1976; 16: 135–8
   PubMed Web of Science ®Google Scholar
• Schmidt CL. Endometriosis: a reappraisal of pathogenesis and treatment. Fertil Steril 1985; 44: 157–73
   PubMed Web of Science ®Google Scholar
• Evers J LH. The pregnancy rate of the no-treatment group in randomized clinical trials of endometriosis therapy. Fertil Steril 1989; 52: 906–7
   Google Scholar
• Ylikorkala O, Dawood MY. New concepts in dysmenorrhea. Am J Obstet Gynecol 1978; 130: 833–47
   PubMed Web of Science ®Google Scholar
• Kauppila A, Telimaa S, Ronnberg L. Menstrual pain in endometriosis. Frontiers in gynecological endocrinology series. Pain and reproduction, AR Genazzani, G Nappi, F Facchinetti, E Martignoni. The Parthenon Publishing Group, Casterton Hall, Carnforth, LancasterUK 1988; 69–74
   Google Scholar
• Barbieri RL. Endometriosis 1990. Current treatment approaches. Drugs 1990; 39: 502–10
   PubMed Web of Science ®Google Scholar
• Karnaky KJ. The use of stilbestrol for endometriosis. South Med J 1948; 41: 1109–11
   PubMedGoogle Scholar
• Merril JA. Benign lesions of the cervix, corpus, tubes and ovaries. Textbook of Obstetrics and Gynecology, 2nd ed., DN Danforth. Harper & Row, Hagertown, MD 1966; 888
   Google Scholar
• Kistner RW. Current status of the hormonal treatment of endometriosis. Clin Obstet Gynecol 1966; 9: 271–92
   PubMedGoogle Scholar
• Kistner RW. The use of newer progestins in the treatment of endometriosis. Am J Obstet Gynecol 1958; 75: 264–78
   PubMed Web of Science ®Google Scholar
• Kistner RW. The treatment of endometriosis by inducing pseudo-pregnancy with ovarian hormones: a report of 58 cases. Fertil Steril 1959; 10: 539–56
   Web of Science ®Google Scholar
• Moghissi KS. Treatment of endometriosis with estrogen-progestin combination and progestin alone. Clin Obstet Gynecol 1988; 31: 823–8
   PubMed Web of Science ®Google Scholar
• Dmowski WP, Scholer H FL, Mahesh VB, Greenblatt RB. Danazol - a synthetic steroid derivative with interesting physiological properties. Fertil Steril 1971; 22: 9–18
   PubMed Web of Science ®Google Scholar
• Greenblatt RB, Dmowski WP, Mahesh VB, Scholer H FL. Clinical studies with an antigonadotropin - danazol. Fertil Steril 1971; 22: 102–12
   PubMed Web of Science ®Google Scholar
• Azadian-Boulanger G, Secchi J, Tournemine C, Sakiz E, Vige P, Henrion R. Hormonal activity profile of drugs for endometriosis therapy. Medical management of endometriosis, JP Raynaud. Raven Press, New York 1984; 125–48
   Google Scholar
• Meldrum DR, Chang RJ, Lu Vale J, Rivier J, Judd HL. ‘Medical oophorectomy’ using a long-acting GnRH agonist - a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab 1982; 54: 1081–3
   PubMed Web of Science ®Google Scholar
• Lemay A, Quesnel G. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinzing hormone-releasing hormone (LH-RH) agonist. Fertil Steril 1982; 38: 376–9
   PubMed Web of Science ®Google Scholar
• Schriock E, Monroe SE, Henzl M, Jaffe RB. Treatment of endometriosis with a potent agonist of gonadotropin-releasing hormone (nafarelin). Fertil Steril 1985; 44: 583–8
   PubMed Web of Science ®Google Scholar
• Olive DL. Medical treatment: Alternatives to danazol. Endometriosis. Contemporary concepts in clinical management, RS Schenken. JB Lippincott, Philadelphia 1989; 189–211
   Google Scholar
• Bracken MB. Clinical trials and the acceptance of uncertainty. BMJ 1987; 294: 1111–2
   Google Scholar
• Barbieri RL, Ryan KJ. Danazol: endocrine pharmacology and therapeutic applications. Am J Obstet Gynecol 1981; 141: 453–63
   PubMed Web of Science ®Google Scholar
• Haber GM, Behelak YF. Preliminary report on the use of tamoxifen in the treatment of endometriosis. Am J Obstet Gynecol 1987; 156: 582–6
   Google Scholar
• Kettel LM, Murphy AA, Mortola JF, Liu JH, Ulmann A, Yen S SC. Endocrine responses to long-term administration of the antiprogesterone RU 486 in patients with pelvic endometriosis. Fertil Steril 1991; 56: 402–7
   PubMed Web of Science ®Google Scholar
• Thomas EJ, Cooke ID. Impact of gestrinone on the course of asymptomatic endometriosis. BMJ 1987; 294: 272–4
   PubMedGoogle Scholar
• Telimaa S, Puolakka J, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecol Endocrinol 1987; 1: 51–61
   Google Scholar
• Mahmood TA, Templeton A. The impact of treatment on the natural history of endometriosis. Human Reprod 1990; 5: 965–70
   PubMedGoogle Scholar
• Jenkins G. Review: The mechanism of action of danazol a novel steroid derivative. Aust NZJ Obstet Gynaecol 1980; 20: 113–8
   Google Scholar
• Kauppila A, Ronnberg L, Vihko Danazol R. Gynecological Endocrinology, AR Genazzani, A Volpe, F Fac-Ehinetti. The Parthenon Publishing Group, Casterton Hall, Carnforth, LancasterUK 1987; 595–601
   Google Scholar
• Bayer SR, Seibel MM. Medical treatment: Danazol. Endometriosis. Contemporary concepts in clinical management, RS Schenken. JB Lippincott Company, Philadelphia 1989; 169–87
   Google Scholar
• Wentz AC, Jones GS, Sapp KC, King TM. Progestational activity of danazol in the human female subjects. Am J Obstet Gynecol 1976; 126: 378–84
   Google Scholar
• Kauppila A, Isotalo H, Kivinen S, Stenback F, Vihko R. Short-term effects of danazol and high-dose medroxyprogesterone acetate on cytosol and nuclear estrogen and progestin receptors and 17P-hydroxysteroid dehydrogenase activity histopathology and ultrastructure of human endometrial adenocarcinoma. Int J Cancer 1985; 35: 157–63
   PubMedGoogle Scholar
• Kokko E, Janne O, Kauppila A, Vihko R. Effects of tamoxifen, medroxyprogesterone acetate and their combination on human endometrial estrogen and progestin receptor concentrations, 17 p-hydroxysteroid dehydrogenase activity, and serum hormone concentrations. Am J Obstet Gynecol 1982; 143: 382–8
   PubMed Web of Science ®Google Scholar
• Fedele L, Marchini M, Bianchi S, Baglioni A, Bocciolone L, Nava S. Endometrial patterns during danazol and bu-serilin therapy for endometriosis: comparative structural and ultrastructural study. Obstet Gynecol 1990; 76: 79–84
   Google Scholar
• Marchini M, Fedele L, Bianchi S, Arcaini L, Brioschi D, Di-Nola G. Endometrial patterns during danazol and cyproterone acetate treatment for endometriosis: structural and ultrastructural study. Eur J Obstet Gynecol re-prod Biol 1991; 40: 137–40
   Google Scholar
• Kokko E, Janne O, Kauppila A, Ronnberg L, Vihko R. Danazol has progestin-like actions on the human endometrium. Acta Endocrinol (Copenhagen) 1982; 99: 588–93
   Google Scholar
• Vierikko P, Kauppila A, Ronnberg L, Vihko R. Steroidal regulation of endometriosis tissue: lack of induction of 17P-hydroxysteroid dehydrogenase activity by proges-teron, medroxyprogesterone acetate, or danazol. Fertil Steril 1985; 43: 218–24
   PubMed Web of Science ®Google Scholar
• Noble AD, Lethworth AT. Medical treatment of endometriosis: a comparative trial. Postgr Med J 1979; 55: 37–9, suppl 5
   Google Scholar
• Telimaa S, Ronnberg L, Kauppila A. Placebo-controlled comparison of danazol and high-dose medroxyprogesterone acetate in the postoperative treatment of endometriosis. Gynecol Endocrinol 1987; 1: 363–71
   PubMedGoogle Scholar
• Salat-Baroux J, Giacomini P, Antoine JM. Laparoscopic control of danazol therapy on pelvic endometriosis. Human Reprod 1988; 3: 197–200
   Google Scholar
• Fayez JA, Collazo LM, Vernon C. Comparison of different modalities of treatment for minimal and mild endometriosis. Am J Obstet Gynecol 1988; 159: 927–32
   Google Scholar
• Nisolle-Pochet M, Casanas-Roux F, Donnez J. Histologic study of ovarian endometriosis after hormonal therapy. Fertil Steril 1988; 49: 423–6
   Google Scholar
• Igarashi M. A new therapy for pelvic endometriosis and uterine adenomyosis: local effect of vaginal and intrauterine danazol application. Asia-Oceania J Obstet Gynecol 1990; 16: 1–12
   PubMedGoogle Scholar
• Burry KA, Patton PE, Illingworth DR. Metabolic changes during medical treatment of endometriosis: Nafarelin versus danazol. Am J Obstet Gynecol 1989; 160: 1454–61
   Google Scholar
• Nilsson B, Sodergard R, Damber M-G, Schoultz B. Danazol and gestagen displacement of testosterone and influence of sex-hormone-binding-globulin capacity. Fertil Steril 1982; 38: 48–53
   PubMed Web of Science ®Google Scholar
• Tummon IS, Pepping ME, Binor Z, Radwanska E, Dmowski WP. A randomized prospective comparison of endocrine changes induced with intranasal leuprolide or danazol for treatment of endometriosis. Fertil Steril 1989; 51: 390–4
   PubMed Web of Science ®Google Scholar
• Telimaa S, Apter D, Reinila M, Ronnberg L, Kauppila A. Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate. Eur J Obstet Gynecol Reprod Biol 1990; 36: 97–105
   Google Scholar
• Fahraeus L, Larsson-Cohn U, Ljungberg S, Wallentin L. Profound alterations of the lipoprotein metabolism during danazol treatment of premenopausal women. Fertil Steril 1984; 42: 52–7
   Google Scholar
• Telimaa S, Penttila I, Puolakka J, Ronnberg L, Kauppila A. Circulating lipid and lipoprotein concentrations during danazol and high-dose medroxyprogesterone acetate therapy of endometriosis. Fertil Steril 1989; 52: 31–5
   Google Scholar
• Crook D, Gardner R, Worthington M, Nolan J, Stevenson JC, Shaw RW. Zoladex versus danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors. Horm Res 1989; 32: 157–60
   Google Scholar
• Luciano AA, Hauser KC, Chapler FK, Sherman BM. Effects of danazol on plasma lipid and lipoprotein levels in healthy women with endometriosis. Am J Obstet Gynecol 1983; 145: 422–6
   Google Scholar
• Pearson K, Zimmerman HJ. Danazol and liver damage. Lancet 1980; 1: 645–6
   Google Scholar
• Janne O, Kauppila A, Kokko E, Lantto T, Ronnberg L, Vihko R. Estrogen and progestin receptors in endometriosis lesions: comparison with endometrial tissue. Am J Obstet Gynecol 1981; 141: 562–6
   PubMed Web of Science ®Google Scholar
• Bergqvist A, Rannevik G, Thorell J. Estrogen and progesterone cytosol receptor concentration in endometriotic tissue and intrauterine endometrium. Acta Obstet Gynecol Scand 1981; 53–8, Suppl 101
   Google Scholar
• Kauppila A, Vierikko P, Isotalo H, Ronnberg L, Vihko R. Cytosol estrogen and progestin receptor concentrations and 17 p-hydroxysteroid dehydrogenase activity in the endometrium and endometriotic tissue. Effects of hormone treatment. Acta Obstet Gynecol Scand 1984; 45–9, Suppl 123
   Google Scholar
• Lessey BA, Metzger DA, Haney AF, McCarty KS. Im-munohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril 1989; 51: 409–15
   PubMedGoogle Scholar
• Luciano AA, Turksoy RN, Carleo J. Evaluation of oral medroxyprogesterone acetate in the treatment of endometriosis. Obstet Gynecol 1988; 72: 323–7
   PubMed Web of Science ®Google Scholar
• Gunning JE, Moyer D. The effect of medroxyprogesterone acetate on endometriosis in the human female. Fertil Steril 1967; 18: 759–74
   Google Scholar
• Hull ME, Moghissi KS, Magyar DF, Hayes MF. Comparison of different treatment modalities of endometriosis in infertile women. Fertil Steril 1987; 47: 40–4
   PubMed Web of Science ®Google Scholar
• Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981; 304: 560–3
   PubMed Web of Science ®Google Scholar
• Teichmann AT, Cremer P, Wieland H, Kuhn W, Seidel D. Lipid metabolic changes during hormonal treatments of endometriosis. Maturitas 1988; 10: 27–33
   Google Scholar
• Fahraeus L, Sydsjo A, Wallentin L. Lipoprotein changes during treatment of pelvic endometriosis with medroxyprogesterone acetate. Fertil Steril 1986; 45: 503–6
   PubMed Web of Science ®Google Scholar
• Timonen S, Johansson CJ. Endometriosis treated with lynestrenol. Ann Chir Gynaecol Fenn 1968; 57: 144–7
   PubMedGoogle Scholar
• Mettler L. Vegleich der medikamentosen Behandlung der Endometriosis Genitalis Externa mit Gestrinon Lynestrenol und Danazol in Rahmen-Stufen-Behandlung. Fertility 1987; 3: 133–9
   Google Scholar
• Riva HL, Kawasaki DM, Messinger AJ. Further experience with norethynodrel in treatment of endometriosis. Obstet Gynecol 1962; 16: 111–7
   Google Scholar
• Schlaff WD, Dugoff L, Damewood MD, Rock JA. Meges-trol acetate for treatment of endometriosis. Obstet Gynecol 1990; 75: 646–8
   PubMed Web of Science ®Google Scholar
• Fedele L, Arcaini L, Bianchi S, Baglioni A, Vercellini P. Comparison of cyproterone acetate and danazol in the treatment of pelvic pain associated with endometriosis. Obstet Gynecol 1989; 73: 1000–4
   Google Scholar
• Johnston WI. Dydrogesterone and endometriosis. Br J Obstet Gynecol 1976; 83: 77–80
   PubMedGoogle Scholar
• Köhler G, Goretzlehner G, Brachmann K. Lipid metabolism during treatment of endometriosis with the progestin dienogest. Acta Obstet Gynecol Scand 1989; 68: 633–5
   PubMed Web of Science ®Google Scholar
• Simon JA, Shangold MM, Andrews MC, Buster JE, Hodgen GD. Micronized progesterone therapy: the importance of route of administration and pharmacocinetics on clinical outcome. Contraception, fertilite, sexualite: International symposium ESHRE, The Hague, 6th July, 1992, 13–8
   Google Scholar
• Fedele L, Marchini M, Baglioni A, Dell-Antonio G, Motta T. Evaluation of histological and ultrastructural aspects of endometrium during treatment with gestrinone in women with amenorrhea or spotting. Acta Obstet Gynecol Scand 1990; 69: 143–6
   Web of Science ®Google Scholar
• Kauppila A, Isomaa V, Vierikko P, Vihko R. Effect of gestrinone in endometriosis tissue and endometrium. Fertil Steril 1985; 44: 466–70
   PubMed Web of Science ®Google Scholar
• Pugeat M, Nicolas B, Tourniaire J, Forest MG. Interaction of gestrinone with human plasma steroid-binding proteins. Medical management of endometriosis, J-P Raynaud, T Ojasoo, L Martini. Raven Press, New York 1984; 183–192
   Google Scholar
• Fedele L, Bianchi S, Viezzoli T, Arcaini L, Candiani GB. Gestrinone versus danazol in the treatment of endometriosis. Fertil Steril 1989; 51: 781–5
   PubMed Web of Science ®Google Scholar
• Thomas EJ, Cooke ID. Impact of gestrinone on the course of asymptomatic endometriosis. BMJ 1987; 294: 272–1
   PubMedGoogle Scholar
• Kiesel L, Bertges K, Von Hoist TR, Runnebaum B. Thera-pie der Endometriose. Arch Gynecol Obstet 1989; 245: 937–40
   Google Scholar
• Donnez J, Nisolle M, Clerckx F, Casanas F. Evaluation of preoperative use of danazol, gestrinone, lynestrenol, buserilin spray and buserilin implant in the treatment of endometriosis associated infertility. Current Concepts in endometriosis. Progr Clin Biol Res 1990; 323: 427–12
   Google Scholar
• Hornstein MD, Gleason RE, Barbieri RL. A randomized double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis. Fertil Steril 1990; 53: 237–41
   Google Scholar
• Coutinho EM, Azadian-Boulanger G. Treatment of endometriosis by vaginal administration of gestrinone. Fertil Steril 1988; 49: 418–22
   PubMed Web of Science ®Google Scholar
• Shaw RW. GnRH analoques in the treatment of endometriosis - rationale and efficacy. Modern approaches to endometriosis, E Thomas, J Rock. J. Kluwer Academic Publishers, London 1990; 257–74
   Google Scholar
• Lemay A, Maheux R, Dodin-Dewailly S. Efficacy and safety on GnRH agonists as compared to danazol in the treatment of endometriosis. The treatment of endometriosis - and other disorders and infections, Y Boutaleb, A Gzouli. The Parthenon Publishing Group. Casterton Hall, Carnforth, LancasterUK 1991; 17–30
   Google Scholar
• Pahwa GS, Kullander S, Vollmer G, Oberheuser F, Knup-Pen R, Emons G. Specific binding sites for gonadotropin releasing hormone in human endometrial adenocarcinoma. Eur J Obstet Gynecol 1991; 41: 135–42
   Google Scholar
• Dlugi AM, Miller JD, Knittle J, Group Lupron Study. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study 1990; 54: 419–27
   Google Scholar
• Henzl MR, Corson SL, Moghissi K, Buttram VC, Bergvist C, Jacobson J. Administration of nasal nafarelin as compared with oral danazol for endometriosis: a multicenter double-blind comparative clinical trial. N Engl J Med 1988; 318: 485–9
   PubMed Web of Science ®Google Scholar
• Henzl MR, Kwei L. Efficacy and safety of nafarelin in the treatment of endometriosis. Am J Obstet Gynecol 1990; 162: 570–4
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Williams IA, Brodribb J, Barlow DH, Shaw RW. A comparison of nafarelin acetate and danazol in the treatment of endometriosis. Fertil Steril 1990; 53: 998–1003
   PubMed Web of Science ®Google Scholar
• Rolland R, Van der Heijden PF. Nafarelin versus danazol in the treatment of endometriosis. Am J Obstet Gynecol 1990; 162: 586–8
   PubMed Web of Science ®Google Scholar
• The Nafarelin European Endometriosis Trial Group (NEET). Nafarelin for endometriosis: a large-scale, dana-zol-controlled trial on efficacy and safety with one-year follow-up. Fertil Steril 1992; 57: 514–22
   PubMed Web of Science ®Google Scholar
• Shaw RW. Zoladex Endometriosis Study Team. An open randomized comparative study of the effect of goserilin depot and danazol in the treatment of endometriosis. Fertil Steril 1992; 58: 265–72
   PubMed Web of Science ®Google Scholar
• Trabant H, Widdra W, De Looze S. Efficacy and safety of intranasal buserilin acetate in the treatment of endometriosis: a review of six clinical trials and comparison with danazol. Prog Clin Biol Res 1990; 323: 357–82
   PubMedGoogle Scholar
• Dawood MY, Lewis V, Ramos J. Cortical and trabecular bone mineral content in women with endometriosis: effect of gonadotropin releasing hormone agonist and danazol. Fertil Steril 1989; 52: 21–6
   Google Scholar
• Riis BJ, Christiansen C, Johansen JS, Jacobson J. Is it possible to prevent bone loss in young women treated with luteinizing hormone-releasing hormone agonists. J Clin Endocrinol Metab 1990; 70: 920–4
   PubMed Web of Science ®Google Scholar
• Surrey ES, Gambone JC, Lu J KH, Judd HL. The effects of combining norethindrone with a gonadotropin-re-leasing hormone agonist in the treatment of symptomatic endometriosis. Fertil Steril 1990; 53: 620–6
   Google Scholar
• Cedars MI, Lu J KH, Meldrum DR, Judd HL. Treatment of endometriosis with a long-acting gonadotropin-re-leasing hormone agonist plus medroxyprogesterone acetate. Obstet Gynecol 1990; 75: 641–5
   PubMed Web of Science ®Google Scholar
• Maouris P. A new treatment for endometriosis. Lancet 1989; 1: 1017–8
   Google Scholar
• Rosen A, Klein M, Beck A. Transdermal oestrogene application a contraindication in therapy of endometriosis with gonadotropin-releasing hormone analogues. Klin Wochenschr 1990; 68: 537–9
   Google Scholar
• Tuimala R, Elomaa K, Kiilholma P, Korhonen M, Vilska S, Saaranen M, Kivinen S, Niemi K, Hagman E, Heikkila M. A Placebo-controlled comparative study of the effects of Zoladex depot and Zoladex depot plus Kliogest in the treatment of endometriosis. Advances in the study of GnRH analoques, B Lunenfeld. The Parthenon Publishing Group, Casterton Hall, Carnforth, LancasterUK 1990; Vol 3: 151–7
   Google Scholar
• Barbieri RL. Hormone treatment of endometriosis: The estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166: 740–7
   PubMed Web of Science ®Google Scholar
• Donnez J, Lemaire-Rubbers M, Karaman Y, Nisolle-Po-Chet M, Casanas-Roux F. Combined (hormonal and microsurgical) therapy in infertile women with endometriosis. Fertil Steril 1987; 48: 239–42
   PubMed Web of Science ®Google Scholar
• Redwine DB. Conservative laparoscopic excision of endometriosis by sharp dissection: life table analysis of reoperation and persistent or recurrent disease. Fertil Steril 1991; 56: 628–34
   PubMed Web of Science ®Google Scholar
• Telimaa S. Danazol and medroxyprogesterone acetate inefficacious in the treatment of infertility of endometriosis. Fertil Steril 1988; 50: 872–5
   PubMed Web of Science ®Google Scholar
• Thomas EJ. Endometriosis and infertility. Modern approaches to endometriosis, E Thomas, J Rock. Kluwer Academic Publishers, London 1990; 113–28
   Google Scholar
• Thomas EJ, Cooke ID. Successful treatment of asymptomatic endometriosis: does it benefit infertile women. BMJ 1987; 294: 117–9
   Google Scholar
• Seibel MM, Berger MJ, Weinstein FG, Taymor ML. The effectiveness of danazol on subsequent infertility in minimal endometriosis. Fertil Steril 1982; 38: 534–7
   PubMed Web of Science ®Google Scholar
• Bayer SR, Seibel MM, Saffan DS, Berger MJ, Taymor ML. Efficacy of danazol treatment for minimal endometriosis in infertile women a prospective randomized study. J Reprod Med 1988; 33: 179–83
   PubMed Web of Science ®Google Scholar
• Fedele L, Parazzini F, Radici E, Bocciolone L, Bianchi S, Bianchi C, Candiani GB. Buserilin acetate versus expectant management in the treatment of infertility associated with minimal or mild endometriosis: A randomized clinical trial. Am J Obstet Gynecol 1992; 166: 1345–50
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Arcaini L, Vercellini P, Candiani GB. Buserilin versus danzol in the treatment of endometriosis-associated infertility. Am J Obstet Gynecol 1989; 161: 871–6
   PubMed Web of Science ®Google Scholar
• Toma S, Stovall DW, Hammond MG. The effect of laparoscopic ablation or danocrine on pregnancy rates in patients with stage I or II endometriosis undergoing donor insemination. Obstet Gynecol 1992; 80: 253–6
   Google Scholar
• Chong AP, Keene ME, Thornton NL. Comparison of three modes of treatment for infertility patients with minimal pelvic endometriosis. Fertil Steril 1990; 53: 407–10
   Google Scholar
• Kauppila A, Rajaniemi H, Ronnberg L, Vihko R. Receptor disorders in endometriosis. Contr Gynecol Obstet 1987; 16: 40–7
   Google Scholar
• Schenken RS, Riehl RM. In vitro fertilization/embryo transfer and gamete intrafallopian transfer. Endometriosis. Contemporary concepts in clinical management, RS Schenken. JB Lippincott, Philadelphia 1989; 293–305
   Google Scholar
• Deaton JL, Gibson M, Blackmer KM, Nakajima ST, Badger GJ, Brumsted JR. A randomized controlled trial of clomiphene citrate and intrauterine insemination in couples with unexplained infertility or surgically corrected endometriosis. Fertil Steril 1990; 54: 1083–8
   PubMed Web of Science ®Google Scholar
• Oehninger S, Rosenwaks Z. In vitro fertilization and em-bryo transfer: an established and successful therapy for endometriosis. Progr Clin Biol Res 1990; 323: 319–35
   Google Scholar
• Chillik C, Acosta A, Garcia JE, Perera S, Van Uem JF, Rosenwaks Z, Jones H, Jr. The role of in vitro fertilization in infertile patients with endometriosis. Fertil Steril 1985; 44: 56–61
   PubMed Web of Science ®Google Scholar
• Fedele L, Bianchi S, Marchini M, Villa L, Brioschi D, Parazzini F. Superovulation with human menopausal gonadotropins in the treatment of infertility associated with minimal or mild endometriosis: a controlled randomized study. Fertil Steril 1992; 58: 28–31
   PubMed Web of Science ®Google Scholar
• Serta RT, Rufo S, Seibel MM. Minimal endometriosis and intrauterine insemination: does controlled ovarian hyperstimulation improve pregnancy rates. Obstet Gynecol 1992; 80: 37–40
   Google Scholar
• Sampson JA. Peritoneal endometriosis due to menstrual dissemination of endometriosis tissue into the peritoneal cavity. Am J Obstet Gynecol 1927; 14: 422–69
   Google Scholar
• Buttram VC. Conservative surgery for endometriosis in the infertile female: A study of 206 patients with implications for both medical and surgical therapy. Fertil Steril 1979; 31: 117–23
   PubMed Web of Science ®Google Scholar
• Liu D TY, Hitchock A. Endometriosis: its association with retrograde menstruation dysmenorrhoea and tubal pathology. Brit J Obstet Gynaecol 1986; 93: 859–62
   PubMedGoogle Scholar
• Scommegna A. Secondary dysmenorrhea: endometriosis. Dysmenorrhea, MY Dawood. William & Wilkins, Baltimore 1981; 131–54
   Google Scholar
• Fedele L, Bianchi S, Bocciolone L, Nola GD, Parazzini F. Pain symptoms associated with endometriosis. Obstet Gynecol 1992; 79: 767–9
   PubMed Web of Science ®Google Scholar
• Willman EA, Collins WP, Clayton SG. Studies in the involvement of prostaglandins in the uterine symptomalo-gy and pathology. Brit J Obstet Gynaecol 1976; 83: 337–41
   PubMedGoogle Scholar
• Drake TS, O'Brien WF, Ramwell PW, Metz SA. Peritoneal fluid thromboxane B2 and 6-ketoprostaglandin F14 in endometriosis. Am J Obstet Gynecol 1981; 140: 401–4
   PubMed Web of Science ®Google Scholar
• Dawood MY, Khan-Dawood FS, Wilson L, Jr. Peritoneal fluid prostaglandins and prostanoids in women with endometriosis, chronic inflammatory disease, and pelvic pain. Am J Obstet Gynecol 1984; 148: 391–5
   PubMedGoogle Scholar
• Ylikorkala O, Koskimies A, Laaatikainen T, Tenhunen A, Viinikka L. Peritoneal fluid prostaglandins in endometriosis, tubal disorders, and unexplained infertility. Obstet Gynecol 1984; 63: 616–20
   Google Scholar
• Badawy S ZA, Marshall L, Cuenca V. Peritoneal fluid prostaglandins in various stages of the menstrual cycle: role in infertile patients with endometriosis. Int J Fertil 1985; 30: 48–52
   Google Scholar
• Khoo SK, Brodie A, Mackay EV. Peritoneal fluid biochemistry in infertile women with mild pelvic endometriosis: prognostic value of prostaglandin F2il concentration to subsequent pregnancy. Aust NZ Obstet Gynaecol 1986; 26: 210–5
   Google Scholar
• DeLeon FD, Vijayaakumar R, Brown M, Rao ChV, Yussman MA, Schultz G. Peritoneal fluid volume, estrogen, progesterone, prostaglandin, and epidermal growth factor concentrations in patients with and without endometriosis. Obstet Gynecol 1986; 68: 189–94
   Google Scholar
• Rock JA, Dubin NH, Ghodgaonkar RB, Bergguist CA, Erozan YS, Kimball AW. Cul-de-sac fluid in women with endometriosis: fluid volume and prostanoid concentration during the proliferative phase of the cycledays 8 to 12. Fertil Steril 1982; 37: 747–50
   PubMed Web of Science ®Google Scholar
• Mäkäräinen L. Studies on uterine contractions and bleeding with special reference to prostanoids. Series D, Medica No 159, Acta Universitas Oulu. 1987
   Google Scholar
• Moon YS, Leung P CS, Ho Yuen B, Gomel V. Prosta-glandin F in human endometriotic tissue. Am J Obstet Gynecol 1981; 141: 344–5
   Google Scholar
• Ylikorkala O, Viinikka L. Prostaglandins and endometriosis. Acta Obstet Gynecol Suppl 1983; 113: 105–9
   Google Scholar
• Kauppila A, Ronnberg L, Ylikorkala O. Prostaglandin biosynthesis inhibitors and endometriosis. Prostaglandins 1979; 18: 655–61
   PubMedGoogle Scholar
• Kauppila A, Ronnberg L. Naproxen sodium in dysmenorrhea secondary to endometriosis. Obstet Gynecol 1985; 65: 379–83
   PubMed Web of Science ®Google Scholar
• Gleicher N. Endometriosis: a new approach is needed. Hum Reprod 1992; 7: 821–4
   PubMedGoogle Scholar
• Rock J, Markham SM. Pathogensis of endometriosis. Lancet 1992; 340: 1264–7
   PubMed Web of Science ®Google Scholar